



Cite this: *Biomater. Sci.*, 2015, **3**, 163

Dual-drug delivery of curcumin and platinum drugs in polymeric micelles enhances the synergistic effects: a double act for the treatment of multidrug-resistant cancer†

Wei Scarano,^a Paul de Souza^b and Martina H. Stenzel^{*a}

Combinational chemotherapy is often used to prevent drug induced resistance in cancer. The aim of this work is to test whether the co-delivery of drugs within one nanoparticle can result in increased synergistic effects of both drugs. Therefore, a micelle system with two different compartments, one for the drug curcumin and one for the conjugation of platinum drugs was designed. A triblock copolymer, based on the biodegradable polycaprolactone PCL, a PEG based shell and an amine bearing polymer as the inter-phase for the conjugation of platinum drugs was prepared by combination of ring-opening polymerization and RAFT polymerization. Curcumin was incorporated into the self-assembled onion-type micelle by physical encapsulation into the PCL core with an entrapment capacity of 6 wt%. The platinum(IV) drug oxoplatin was reacted with succinic anhydride to yield $\text{Pt}(\text{NH}_3)_2\text{Cl}_2[(\text{COOH})_2]$, which acted as the drug and as a crosslinker for the stabilisation of micelles. The size of the dual drug micelles was measured to be 38 nm by DLS, which was confirmed by TEM. The toxicity of the dual drug delivery system was tested against the A2780 human ovarian cancer cell line and compared with the IC_{50} value of micelles that deliver either curcumin or the platinum drug alone. The results were analysed using the CalcuSyn software. While curcumin and the platinum drug together without a carrier already showed synergy with a combination index ranging from 0.4 to 0.8, the combined delivery in one nanoparticle did enhance the synergistic effects resulting in a combination index of approximately 0.2–0.35. For comparison, a mixture of two nanoparticles, one with curcumin and the other with the platinum drug, was tested revealing a less noticeable synergistic effect compared to the co-delivery of both drugs in one drug carrier.

Received 31st July 2014,
Accepted 27th August 2014
DOI: 10.1039/c4bm00272e

www.rsc.org/biomaterialsscience

Introduction

Conventional chemotherapy, if ineffective in eradicating cancer cells, can lead to the development of drug resistance over the course of therapy. The development of drug resistance could be due to two major factors: the inability to deliver drugs to the tumour site and specific genetic alternations in cancer cells.¹ Drug delivery to the tumour site can be improved with the use of nanoparticles and delivery systems such as polymeric micelles have been widely used as drug carriers due to their advantageous characteristics such as solubilisation of hydrophobic molecules with high drug loading capacity, low

toxicity, high water solubility and high structural stability which ultimately allow prolonged circulation in blood and enhanced accumulation in tumour tissues.^{2,3}

To overcome potential drug-induced mutations and drug resistance in tumours, combination chemotherapy may be used. This is where a combination of two or more drugs is employed to disrupt different stages of the cell repair and/or reproduction cycle to enhance the apoptosis of cancer cells. In cancer treatment it is common to utilise a combination of chemotherapeutic agents for treatment,^{4–8} however it is important to consider their mechanism of action, the dose ratios between the drugs as well as their induced side effects.

Cisplatin is one of the commonly used chemotherapeutic agents today; it disrupts cell repair by cross-linking with DNA strands and ultimately causing apoptosis.^{9,10} However a potential disadvantage of using platinum-based drugs is that they are required to enter the cell nucleus first, and then attach to DNA before the apoptosis sequence begins.^{11,12} However, excision repair cross-complementary 1 (ERCC1), a protein involved in the process of nucleotide excision repair, is expressed at

^aCentre for Advanced Macromolecular Design (CAMD), School of Chemistry, University of New South Wales, Sydney, NSW 2052, Australia.
E-mail: M.Stenzel@unsw.edu.au

^bLiverpool Hospital Clinical School, and Molecular Medicine Research Group, University of Western Sydney, Sydney, NSW 2170, Australia


† Electronic supplementary information (ESI) available: NMR, GPC and DLS of the block copolymers. See DOI: 10.1039/c4bm00272e

high levels in cancer and has been associated with resistance to platinum-based chemotherapy.¹³ Therefore cisplatin is often used in conjunction with other drugs for cancer treatment in an attempt to circumvent this potential mechanism of platinum resistance.

Curcumin is a natural polyphenolic compound extracted from the root of turmeric plant (*curcuma longa*) and has been used traditionally for centuries in Asia for medicine, cooking, and other purposes. Curcumin exists in mostly β -diketone tautomer form but also exists between the two equilibrates of the asymmetric keto-enol tautomer,¹⁴ and it possesses antioxidant, anti-inflammatory, antibacterial and anti-cancer activities. Curcumin has been shown to exhibit therapeutic potential against various types of cancers^{15–18} but it has poor bioavailability due to its rapid metabolism in the liver and the intestinal wall. It is understood that the anti-carcinogenic and chemo-preventive effects of curcumin could be due to its action on multiple targets including transcription factors, growth regulators,¹⁹ adhesion molecules, apoptotic genes, angiogenesis regulators and cellular signalling molecules.^{20–22}

The synergistic effect of curcumin and various anticancer agents has been explored previously.^{23–33} However the efficacy of the drug can also be significantly improved with the use of drug delivery systems.³⁴ Drug delivery systems consisting of polymeric materials have been used to deliver a wide range of compounds with the potential of improving the Enhanced Permeability and Retention (EPR) effect on solid tumours.^{35–37} This is where polymeric macromolecular structures of size above 40 kDa are accumulated in solid tumours due to their pathophysiological uniqueness, unlike low molecular weight compounds.^{38,39} Therefore delivering curcumin using a polymeric drug delivery system could also improve its activity.^{40–45} Furthermore, curcumin is able to enhance the antiproliferative properties of platinum complexes.^{13,46–49} The use of liposomes to deliver both platinum and curcumin can result in a greater growth inhibition and an apoptotic effect with virtually no side effects in animals.⁵⁰ However, it has never been quantified whether there is an advantage (or a synergistic effect) in co-delivering both drugs.

We hypothesized therefore that the use of a polymeric micelle delivery system to co-deliver curcumin and platinum complexes would result in improved drug efficacy. Both drugs have very different requirements with regard to an optimized drug carrier design. While curcumin is best delivered using a hydrophobic polymer, platinum drugs are typically conjugated to the polymer.^{51–53} The design of nanocarriers with various compartments of different nature is therefore of paramount importance. Onion-type polymeric micelles based on triblock copolymers with their tuneable characteristics fit the specific requirements. This triblock copolymer needs to satisfy three criteria: a hydrophobic part, which will form the core of the micelle, for the encapsulation of curcumin, a reactive block for the platinum drug conjugation and a water-soluble part that will build up the shell, which determines the interaction with the biological environment. The triblock copolymer will therefore comprise the biodegradable and hydrophobic polymer



Scheme 1 Synthetic route to the triblock copolymer PCL-*b*-PABPA-*b*-POEGMEA followed by the encapsulation of curcumin and crosslinking using Pt[(COOH)₂] for structural stability.

polycaprolactone as the core, a PEG-based polymer as the shell and amine-bearing polymers in the interphase allowing efficient modification for the attachment of desirable molecules. Primary amine based copolymers have been exploited in numerous applications due to their reactivity towards many functional groups such as acids and isocyanates. Furthermore, we propose to use a platinum-based crosslinker that may shield the compound against deactivation by proteins and peptides, as well as strengthen the structural integrity of the micelle itself (Scheme 1).⁵⁴ Crosslinking of micelles has been shown to improve the performance of the drug carrier.^{55,56} The micelles were then tested against the A2780 human ovarian carcinoma cell line. The main focus is the change of the synergistic effects of both drugs when co-delivered in one carrier.

Experimental

Materials

2-Mercapto ethanol (Aldrich, 99%), benzyl bromide (Aldrich, 98%), carbon disulfide (Aldrich, 99%), potassium phosphate, 3-amino-1-propanol (Aldrich, 99%), di-*tert*-butyl-dicarbonate, acryloyl chloride (Aldrich, 97% with <210 ppm MEHQ as the stabilizer), ϵ -caprolactone (Aldrich, 97%), lipase acrylic resin (Aldrich, ≥ 5000 U g⁻¹), fluorescein *O*-methacrylate (Aldrich, 97%), *cis*-diammineplatinum(II) dichloride (CDDP; Sigma Aldrich, 99.9%), *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride (EDC; Aldrich, 98%), *N*-hydroxysuccinimide (NHS; Aldrich, 98%), succinic anhydride (Fluka, 97%), curcumin (Fluka, analytical standard), L-ascorbic acid (Aldrich,

99%), toluene (Aldrich; purum), *N,N*-dimethyl acetamide (DMAc; Aldrich, 99.9%), *N,N*-dimethylformamide (DMF; Aldrich), diethyl ether (Et₂O; Ajax Fine Chem, 99%), ethyl acetate (EtOAc; Ajax Finechem, 99.5%), methanol, anhydrous tetrahydrofuran (THF; Aldrich, >99%), *n*-hexane (Ajax Fine Chem, 95%), hydrochloric acid (HCl; Ajax Fine Chem, 32%), hydrogen peroxide (H₂O₂; Ajax Fine Chem, 30% w/v), 1,4-dioxane (Ajax Fine Chem, 99%), triethylamine (TEA; Ajax Fine Chem, 99%), and potassium phosphate (K₃PO₄; Ajax Fine Chem, 99%) were used without any further purification.

Oligo(ethylene glycol) methyl ether acrylate (OEGMEA, $M_n = 480 \text{ g mol}^{-1}$; Aldrich) was destabilized by passing it over a column of basic alumina and stored at -7°C . 2,2-Azobisisobutyronitrile (AIBN; Fluka, 98%) was purified by recrystallization from methanol. Deionized (DI) water was produced using the Milli-Q water purification system and has a resistivity of $17.9 \text{ m}\Omega \text{ cm}^{-1}$.

Synthesis

Benzyl 2-hydroxyethyl carbonotrithioate (BHCT). Benzyl 2-hydroxyethyl carbonotrithioate (BHCT) was prepared according to the literature.⁵⁷ 2-Mercapto ethanol (1.00 g, 12.82 mmol) was added to a stirred suspension of K₃PO₄ (2.71 g, 12.82 mmol) in acetone (20 mL) and was left to stir for ten minutes. CS₂ (2.92 g, 38.46 mmol) was added and the solution turned bright yellow. After stirring for fifteen minutes benzyl bromide (2.19 g, 12.82 mmol) was added to the reaction to form a precipitation of KBr. The reaction was left to stir overnight at room temperature and the suspension was filtered and the cake was washed with acetone ($2 \times 20 \text{ mL}$). The filtrate was collected and the solvent was removed under reduced pressure on a rotary evaporator to give a yellow viscous oil residue. The product was then purified by column chromatography on silica using a 3:1 hexane–ethyl acetate mixture. Yield: 88%. ¹H-NMR (CDCl₃) δ (ppm): 7.40–7.28 (5H, m, Ph), 4.69 (2H, s, H1), 3.91 (2H, t, H2), 3.66 (2H, t, H3), 2.38 (1H, br, s, H4).

***tert*-Butyl (3-hydroxypropyl)carbamate (BAP).** 3-Amino-1-propanol (10 mL, 133 mmol), di-*tert*-butyl-dicarbonate (43.49 g, 199 mmol) and triethylamine (5 mL) were dissolved in methanol (100 mL). The reaction mixture was stirred at 50°C in an oil bath for 1 h and then it was further reacted at room temperature for 3 h. The solvent was then removed under reduced pressure on a rotary evaporator. Water (50 mL) was then added to the pale yellow oil and the product was extracted using $3 \times$ diethyl ether (30 mL); the diethyl ether layer was then combined and dried over magnesium sulphate. The magnesium sulphate was filtered and the solvent was removed from the filtrate by rotary evaporation to yield pale yellow oil. Yield: 19.78 g, 92%. ¹H-NMR (CDCl₃) δ (ppm): 4.74 (br, 1H, H), 4.26 (t, 2H, H), 3.26 (m, 2H, H), 1.92 (t, 2H, H), 1.47 (s, 9H, H).

3-((*tert*-Butoxycarbonyl)amino)propyl acrylate (ABPA). BOC protected 3-amino-1-propanol (BAP) (4 g, 22.85 mmol) and triethylamine (3.17 mL) were dissolved in anhydrous THF (10 mL) and the reaction mixture was cooled to 0°C in an ice

bath before acryloyl chloride (1.85 mL, 23 mmol) was added dropwise while stirring. The reaction was left to stir in an ice bath for 2 h and then left to react further at room temperature overnight. Any solid was filtered off and the solvent of the filtrate was removed under reduced pressure on a rotary evaporator. The product was purified by gel column chromatography using chloroform as the eluent. The second fraction was collected to obtain clear oil. Yield: 4.1 g, 85%. ¹H-NMR (CDCl₃) δ (ppm): 6.44 (dd, 1H, H1), 6.12 (dd, 1H, H2), 5.87 (dd, 1H, H3), 4.74 (br, 1H, H4), 4.26 (t, 2H, H5), 3.26 (m, 2H, H6), 1.92 (t, 2H, H7), 1.47 (s, 9H, H8).

Polymerisation of ϵ -caprolactone by ring opening polymerisation (ROP). Under a nitrogen atmosphere, a mixture of BHCT (100 mg, 0.39 mmol), ϵ -caprolactone (2 g, 17.54 mmol), toluene (3 mL) and lipase acrylic resin (100 mg) was placed in a dry Schlenk flask. The solution was stirred at 70°C for 1.5 h. After cooling down to room temperature, the lipase acrylic resin was removed by filtration. The polymer was precipitated from the filtrate in a cold mixture of diethylether–*n*-hexane (1:1). Yield: 50 repeating units of ϵ -caprolactone. 1.94 g, GPC (THF): $M_n = 5300 \text{ g mol}^{-1}$, $\text{PDI}_{\text{SEC}} = 1.85$.

RAFT polymerisation with polyethyleneglycol methylether acrylate (OEGMEA) using poly ϵ -caprolactone BHCT (PCL-*b*-POEGMEA). OEGMEA (1 g, 2 mmol), fluorescein *O*-methacrylates (3 mg, $7.5 \times 10^{-3} \text{ mmol}$), AIBN (2.18 mg, $1.3 \times 10^{-2} \text{ mmol}$) and poly ϵ -caprolactone BHCT (216 mg, $4.1 \times 10^{-2} \text{ mmol}$) were dissolved in toluene (1.5 mL). The reaction mixture was placed in an ice bath and purged with nitrogen for 30 minutes. Then the reaction vial was immersed in a preheated oil bath at 65°C for 2.5 h. The polymerization was terminated by placing the samples in an ice bath for 5 min and the polymer was purified by precipitation in cold diethyl ether. After centrifugation (7000 rpm for 10 min), the polymer was dried under reduced pressure at room temperature. The samples were stored in a freezer prior to any modification. By comparing the intensity of vinyl proton peaks (6.1 and 5.6 ppm) with that of aliphatic proton peaks (1.1–1.3 ppm), the conversion of the monomer in the course of polymerization was determined. The monomer conversion was calculated to be 35% by ¹H-NMR yielding 37 repeating units of OEGMEA with $M_{n(\text{theo})} = 22\,960 \text{ g mol}^{-1}$ ($M_{n(\text{SEC DMAc})} = 23\,500 \text{ g mol}^{-1}$) PCL₅₀-*b*-POEGMEA₃₇ was used for chain extension in subsequent reactions.

Synthesis of PCL-*b*-PABPA-*b*-POEGMEA. PCL₅₀-*b*-POEGMEA₃₇ (0.44 g, 0.019 mmol), AIBN (0.20 mg, $1.22 \times 10^{-3} \text{ mmol}$) and ABPA (200 mg, 0.92 mmol) were dissolved in toluene (0.625 mL). The reaction mixture was placed in an ice bath and purged with nitrogen for 30 minutes. Then the reaction vial was immersed in a preheated oil bath at 65°C for 2.5 h. The polymerization was terminated by placing the sample in an ice bath for 5 minutes open to air. The polymer was then purified by precipitation in cold diethyl ether. After centrifugation (7000 rpm for 10 min), the polymer was dried under reduced pressure at room temperature. The samples were stored in a freezer prior to any modification. By comparing the intensity of the vinyl proton peaks at 6.44–6.12 ppm with that of the *tert*

butyl proton peaks at 1.47 ppm, the conversion of monomer in the course of polymerization was determined. The monomer conversion was calculated to be 65% with 38 repeating units of ABPA giving $M_{n(\text{theo})} = 31\,054\text{ g mol}^{-1}$ ($M_{n(\text{SEC DMAC})} = 30\,000\text{ g mol}^{-1}$). The polymer PCL₅₀-*b*-ABPA₃₈-*b*-POEGMEA₃₇ was stored in the dark and dry area for future reactions.

Deprotection of PCL-*b*-PABPA-*b*-POEGMEA into PCL-*b*-PAPA-*b*-POEGMEA. PCL-*b*-ABPA-*b*-POEGMEA (20 mg, mmol) was dissolved in DMF (3 mL) and 2 drops of hydrochloric acid (32%) were added to the reaction mixture and was left to stir overnight at room temperature. The polymer was then precipitated in cold diethyl ether and dried in a vacuum oven at 40 °C. By comparing the disappearance of the *tert*-butyl peaks (1.48–1.5 ppm) the success of the deprotection was confirmed.

Preparation of blank polymeric micelles. PCL-*b*-PABPA-*b*-POEGMEA (10 mg) or PCL-*b*-PAPA-*b*-POEGMEA (10 mg) was dissolved in DMF (2 mL) and water (2.5 mL) was added dropwise over a period of 3 hours. The solution was dialyzed against water for 48 h with constant water change using a tubular dialysis membrane (MWCO 3500).

***cis,cis,trans*-[Pt(NH₃)₂Cl₂(OH)₂] (oxoplatin).** Oxoplatin was synthesized according to the literature.⁵⁴ A mixture of cisplatin (1.0 g, 3.05 mmol) and H₂O₂ 30% w/v (3.5 mL, 30.5 mmol) in an aluminum foil covered round-bottom flask was heated at 70 °C for 5 h. The heat was then removed and the reaction mixture was stirred overnight. The product was recrystallized *in situ* at 4 °C. The product was obtained by vacuum filtration and washed with ice cold water, ethanol, and diethyl ether. After filtration, the solvent was removed under reduced pressure to give the expected product as a bright yellow powder. Yield 90%.

Synthesis of *cis,cis,trans*-diaminedichloro disuccinatoplatinum(IV) (Pt IV(COOH)₂). The platinum complex was prepared according to the literature.⁵⁴ Succinic anhydride (228 mg, 2.278 mmol) was added to a suspension of oxoplatin (200 mg, 0.600 mmol) in DMF (4 mL), and the reaction mixture was stirred at 70 °C for 24 h. During this reaction, the solid material was dissolved to form a yellow-brown solution. DMF was then removed under reduced pressure. The residue was dissolved in acetone and filtered to give a clear, yellow solution. This solution was concentrated under reduced pressure, and subsequent purification by addition of diethyl ether led to precipitation of a pale-yellow solid. The product was dried in a vacuum oven for 2 days. Yield: 131.5 mg (65%).

Synthesis of curcumin loaded micelles (M1 cuc). PCL₅₀-*b*-PABPA₃₈-*b*-POEGMEA₃₇ (15 mg, 5.437×10^{-4} mol) and curcumin (2 mg) were dissolved in 1,4-dioxane (2 mL) and water (2.5 mL) was added dropwise over a period of 3 hours. The reaction mixture was then dialysed against DI water by membrane dialysis (MWCO 3500) for 24 h with frequent water change. The curcumin that was not encapsulated in the micelles precipitated and was removed by centrifugation at 3000 rpm for 5 minutes.

The percent of curcumin incorporated during nanoparticle preparation was determined by taking 100 µL of the particle solution (1 mg mL⁻¹) and diluting with DMF to give a final

volume of 2 mL. The solution was assayed using a UV spectrophotometer at 428 nm and results were obtained using a standard curve. The loading efficiency and entrapment efficiency are calculated by the following formulae:

$$\text{Loading efficiency} = \frac{\text{Total amount of curcumin} - \text{Free curcumin}}{\text{Total amount of curcumin}} \times 100$$

$$\text{Entrapment efficiency} = \frac{\text{Total amount of curcumin}}{\text{Total amount of polymer}} \times 100$$

Synthesis of platinum crosslinked micelles (M2 Pt). PCL₅₀-*b*-PAPA₃₈-*b*-POEGMEA₃₇ (15 mg, 5.437×10^{-4} mol) was dissolved in 1,4-dioxane (2 mL) and water (2.5 mL) was added dropwise over a period of 1 hour. In another vial *N*-hydroxysuccinimide (5 mg, 4.34×10^{-5} mol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EDC (5 mg, 3.22×10^{-5} mol) and Pt(IV) (9 mg, 1.69×10^{-5} mol) were left to react in DI water (1 mL) overnight before adding it to the solution of polymeric micelles. The reaction mixture was left to stir for 48 h, followed by dialysis against DI water using tubular membranes (MWCO 3500).

Synthesis of curcumin loaded and platinum crosslinked micelles (M3). PCL₅₀-*b*-PAPA₃₈-*b*-POEGMEA₃₇ (15 mg, 5.437×10^{-4} mol) and curcumin (1, 2 or 5 mg) were dissolved in 1,4-dioxane (2 mL) and water (2.5 mL) was added dropwise over a period of 3 hours. In another vial NHS (5 mg, 4.34×10^{-5} mol), EDC (5 mg, 3.22×10^{-5} mol) and *cis,cis,trans*-diaminedichlorodisuccinatoplatinum (Pt IV[COOH]₂) (9 mg, 1.69×10^{-5} mol) were left to react in DI water (1 mL) overnight before adding to the reaction mixture containing polymer and curcumin. The reaction mixture was left to stir for 48 h followed by dialysis against DI water for 8 h with hourly water change using a membrane (MWCO 3500). The curcumin that was not encapsulated in the micelles precipitated out and it was removed by centrifugation at 3000 rpm for 5 minutes. The supernatant was extracted for further use. Note: the ratio between COOH and NH₂ functional groups is 2 : 1.

Reduction of the platinum(IV) drug incorporated into PCL-*b*-ABPA-*b*-POEGMEA crosslinked micelles in the presence of sodium ascorbate. The reduction of the Pt(IV) complex incorporated into the polymeric micelle was carried out in DI water instead of buffer solution to avoid buffer coordination to platinum. The concentration of the stock sodium ascorbate is 5 mM. The concentration of micelles for this experiment is 1 mg mL⁻¹. The reduction of the Pt(IV) complex incorporated micelle with sodium ascorbate was monitored over a week at 37 °C using an incubator. After each time interval 100 µL of the sample was taken out from the dialysis bag and is then diluted up to 10 mL of aqua regia (2% v/v) followed by heating the solution at 90 °C for 5 h. ICP-MS was then performed to determine the platinum concentration in the solution.

Measurement of the release of curcumin in crosslinked and uncrosslinked micelles. Three separate micelle solutions at a concentration of 1 mg mL⁻¹ of the polymer were used for this experiment: one uncrosslinked micelle solution containing no

platinum crosslinker and other two with the platinum crosslinker (mg mL^{-1}). Samples were kept in three separate dialysis bags (MWCO 3500). The uncrosslinked micelle containing curcumin only (M1 cuc) was dialysed against PBS (0.1 M) at pH 7.4, the crosslinked micelle sample containing both curcumin and platinum (M3) was dialysed against PBS (0.1 M) at pH 7.4 as well as water containing 5 mM sodium ascorbate. 100 μL samples were taken from inside the dialysis bag and were then diluted with 1900 μL of DMF (total volume 2 mL). The samples were measured by UV-VIS spectroscopy at a wavelength of 428 nm. The concentration of curcumin was then calculated from a standard curve.

Cell culture

The A2780 cell lines were grown in a ventilated tissue culture flask T-75 using Roswell Park Memorial Institute (RPMI-1640) media containing 10% Foetal Bovine Serum (FBS) and antibiotics. The cells were incubated at 37 °C under a 5% CO_2 humidified atmosphere and passaged every 2–3 days when monolayers at around 80% confluence were formed. The cell density was determined by counting the number of viable cells using a trypan blue dye (Sigma-Aldrich) exclusion test.

Cell viability

The cytotoxicity of PCL-*b*-PABPA-*b*-POEGMEA, cisplatin, oxoplatin, $\text{Pt IV}(\text{COOH})_2$ and curcumin/platinum(IV) incorporated micelles (M3) was measured by a standard sulforhodamine B colorimetric proliferation assay (SRB assay). The SRB assay was established by the U.S. National Cancer Institute for rapid, sensitive, and inexpensive screening of antitumor drugs in microtiter plates. The cells were seeded at a density of 5000 cells per well in 96-well plates containing 200 μL of growth medium per well and incubated for 24 h. The medium was then replaced with fresh medium (200 μL) containing various concentrations of the material being tested.

After 48 h incubation, cells were fixed with trichloroacetic acid 10% w/v (TCA) before washing, incubated at 4 °C for 1 h, and then washed five times with tap water to remove TCA, growth medium, and low molecular weight metabolites. Plates were air dried and then stored until use. TCA-fixed cells were stained for 30 min with 0.4% (w/v) SRB dissolved in 1% acetic acid. At the end of the staining period, SRB was removed and cultures were quickly rinsed five times with 1% acetic acid to remove the unbound dye. Then the cultures were air dried until no conspicuous moisture was visible. The bound dye was shaken for 10 min. The absorbance at 570 nm of each well was measured using a microtiter plate reader scanning spectrophotometer BioTek's PowerWave™ HT Microplate Reader and the KC4™ Software. All experiments were repeated three times. Dose-response curves were plotted (values were expressed as the percentage of control, medium only) and IC_{50} inhibitory concentrations were obtained using the software Graph Pad PRISM 6.

$$\text{Cell viability (\%)} = \frac{(\text{OD}_{490, \text{sample}} - \text{OD}_{490, \text{blank}})}{(\text{OD}_{490, \text{control}} - \text{OD}_{490, \text{blank}})} \times 100$$

Analysis

Size exclusion chromatography (SEC). SEC was implemented using a Shimadzu modular system comprising of a DGU-12A degasser, LC-10AT pump, SIL-10AD automatic injector, CTO-10A column oven, RID-10A refractive index detector, and SPD-10A Shimadzu UV/vis detector. A Phenomenex 50 $\times$ 7.8 mm guard column and four Phenogel 300 $\times$ 7.8 mm linear columns (500, 10^3 , 10^4 , and 10^5 Å pore size, 5 μm particle size) were used for the analyses. *N,N*-Dimethylacetamide (DMAc; HPLC grade, 0.05% w/v LiBr, 0.05% w/v 2,6-dibutyl-4-methylphenol (BHT)) or tetrahydrofuran (THF; HPLC grade) at a flow rate of 1 mL min^{-1} and a constant temperature of 50 °C was used as the mobile phase with an injection volume of 50 μL . The samples were filtered through 0.45 μm filters. The unit was calibrated using commercially available linear polystyrene standards (0.5–1000 kDa, Polymer Laboratories). Chromatograms were processed using the Cirrus 2.0 software (Polymer Laboratories).

Nuclear magnetic resonance (NMR) spectroscopy. ^1H NMR spectra were recorded using a Bruker ACF300 (300 MHz) spectrometer, using $(\text{CD}_3)_2\text{SO}$, CD_3OD , or CDCl_3 as the solvent. All chemical shifts are stated in ppm (δ) relative to tetramethylsilane ($\delta = 0$ ppm), referenced to the chemical shifts of residual solvent resonances.

Dynamic light scattering (DLS). The average hydrodynamic diameters and size distribution of the prepared micelle solution in an aqueous solution at a concentration of 1 mg mL^{-1} were obtained using the Malvern Nano-ZS as a particle size analyzer (laser, 4 mW, $\lambda = 632$ nm; measurement angle 12.8° and 175°). Samples were filtered to remove dust using a micro-filter 0.45 μm prior to the measurements and run at least three times at 25 °C.

Transmission electron microscopy (TEM). The TEM micrographs were obtained using a JEOL 1400 transmission electron microscope. The instrument operates at an accelerating voltage of 100 kV. The samples were prepared by casting the micellar solution (1 mg mL^{-1}) onto a formvar-coated copper grid. No staining was applied.

Thermogravimetric analysis (TGA). TGA studies were carried out under an air atmosphere and the heating rate was fixed at 5 °C min^{-1} on a thermal analyzer TGA 2950HR V5.4A. The temperature profile for analysis ranged between 50 and 1000 °C with a five minute isothermal condition at 100 °C. The mass of the samples used in this study was 10 mg.

UV-VIS spectrophotometry. All measurements were performed using a standard glass cuvette with a Varian Cary 300 UV-VIS Spectrophotometer. The machine scans in the range of wavelengths between 190 and 900 nm with a wavelength accuracy of ± 0.2 nm. The measurements are performed at a scan rate of 3000 nm min^{-1} at the standard temperature of 25 °C.

Inductively coupled plasma-mass spectrometry (ICP-MS). The Perkin-Elmer ELAN 6000 inductively coupled plasma-mass spectrometer (Perkin-Elmer, Norwalk, CT, USA) was used for quantitative determination of platinum. All experiments were

carried out at an incident radio frequency power of 1200 W. The plasma argon gas flow of 12 L min⁻¹ with an auxiliary argon flow of 0.8 L min⁻¹ was used in all cases. The nebulizer gas flow was adjusted to maximize the ion intensity at 0.93 L min⁻¹, as indicated by the mass flow controller. The element/mass detected was 195Pt and the internal standard used was 193Ir. The replicate time was set to 900 ms, and the dwell time was set to 300 ms. Peak hopping was the scanning mode employed and the number of sweeps/readings was set to 3. A total of 10 replicates were measured at the normal resolution.

Results and discussion

Reversible Addition Fragmentation chain Transfer (RAFT) polymerisation is a commonly used technique used for the synthesis of complex polymer architectures. In particular it can be easily combined with other techniques to generate polymer architectures that have degradable properties.⁵⁸ Several approaches are described in the literature to combine polymers prepared by ring-opening polymerization and RAFT polymerization with the initiation of the ring-opening polymerization using a functional RAFT agent being one of them.⁵⁸ Polycaprolactone was chosen as one of the materials for drug delivery carriers due to its biodegradability and biocompatibility. This allows the matrix material to be decomposed into non-toxic and low molecular weight molecules and then metabolized or absorbed by the organism.⁵⁹ Polycaprolactone was synthesized *via* ring-opening polymerization (ROP) of ϵ -caprolactone which was carried out according to the literature.⁶⁰ The reaction was performed under enzymatic conditions at 70 °C in the presence of lipase resin and the benzyl 2-hydroxyethyl carbonotrithioate (BHCT) RAFT agent as the initiator (Scheme 1). The conversion of this reaction was determined by gravimetric analysis and is further confirmed by the ¹H NMR spectra (see ESI Fig. S1†) revealing a PCL block with approximately 50 repeating units and is determined by comparing the peak at 4.633 ppm which belongs to the BHCT RAFT and the peak at 4.097–4.053 ppm of the caprolactone repeated units (Table 1, see ESI Fig. S1 and S2†). The results from SEC and the theoretical value obtained from the conversion were in good agreement especially considering that the SEC was calibrated against polystyrene.

The newly synthesised PCL macroRAFT agent was used for the polymerisation of OEGMEA. The monomer oligo(ethylene glycol)methyl ether acrylate (OEGMEA) was chosen as the

hydrophilic shell of the micelle due to its water solubility and the resemblance to PEG. The monomer OEGMEA had to be polymerized prior to the amine bearing monomer to generate a micelle with a protective water-soluble shell. This was necessary due to the nature of the RAFT agent that carried PCL as part of the Z-group, which led to the monomer insertion close to the PCL block.⁵⁸ The resulting block polymer, named PCL1, had a molecular weight close to the expected value (Table 1, see ESI Fig. S2†).


For the synthesis of the third block a new amine bearing monomer had to be prepared. The purpose of this block was to act as a functional handle for the conjugation of the platinum(IV) crosslinker while enhancing the structural integrity of the polymeric micelle by crosslinking at the nexus. The amine functionality is not only highly reactive, but the resulting amide bond after reaction with the carboxylate-based Pt(IV) crosslinker is also stable in a typical biological environment preventing premature disassembly of the micelle. The protection of amine functional groups is essential prior to the RAFT polymerisation reaction at neutral pH. This is due to the fact that amines would attack the dithioester functional group of the RAFT agent *via* nucleophilic substitution reaction, thus destroying or interfering with the functionality of the RAFT agent itself.^{61,62} Di-*tert*-butyl dicarbonate was used for the protection of 3-amino-1-propanol and the *tert*-butyl carbamates can be easily cleaved under an acidic condition. The monomer was synthesised by reacting acryloyl chloride and BOC protected 3-amino-1-propanol in the presence of an auxiliary base, in this case triethylamine, in anhydrous THF solvent (Scheme 2). The final product was purified *via* gel column chromatography and is soluble in many solvents such as methanol, toluene, and dioxane. Moreover, the monomer was stable, not air sensitive and even after storage in the freezer at -10 °C over several weeks showed no signs of decomposition. The structure of the monomer was confirmed by ¹H NMR (see ESI Fig. S3†).

The PCL₅₀-*b*-PEGMEA₃₇ (PCL1) macroRAFT agent was employed for further chain extension with ABPA to yield the triblock copolymer PCL-*b*-PABPA-*b*-PEGMEA. The molecular weights of the block copolymers are listed in Table 1 and the overlay of SEC chromatograms is shown in the ESI Fig. S2.† Their measured values are close to the theoretical value. In addition, the molecular weight distribution is narrow.

The subsequent removal of the BOC protective group can be easily achieved using strong acids such as hydrochloric acid or trifluoroacetic acid. The polymer was dissolved in an organic solvent such as DMF or dioxane and HCl (2 M in

Table 1 Summary of homopolymers and block copolymers used for the incorporation of curcumin and platinum conjugation

Sample	Polymer	Conv.	M_n^{Theo} (g mol ⁻¹)	M_n^{SEC} (g mol ⁻¹)	PDI _{SEC}
PCL	PCL ₅₀	95%	5900	5200	1.85
PCL1	PCL ₅₀ - <i>b</i> -POEGMEA ₃₇	35%	22 960	23 500	1.37
M1	PCL ₅₀ - <i>b</i> -PABPA ₃₈ - <i>b</i> -POEGMEA ₃₇	65%	31 054	30 000	1.35



Scheme 2 Synthesis route to the ABPA monomer from 3-amino-1-propanol.

diethyl ether) was added to the reaction and was left to stir overnight to yield the deprotected PCL₅₀-*b*-PAPA₃₈-*b*-POEGMEA₃₇. The polymer was then purified *via* dialysis against acetone or water to remove unwanted side products. ¹H-NMR proves the complete removal of the *tert*-butyl carbamate protection group (see ESI Fig. S4†) while SEC analysis confirms that during deprotection no side reaction occurred which might have led to crosslinking or loss of PCL (see ESI Fig. S5†).

Two types of block copolymers were used for the synthesis of micelles prior to drug loading: PCL₅₀-*b*-ABPA₃₈-*b*-POEGMEA₃₇ (M1) with the BOC protection group and PCL₅₀-*b*-APA₃₈-*b*-POEGMEA₃₇ (M2) without the BOC protection group. The size distribution of the nanoparticles is shown in Table 2 with an average hydrodynamic size of about 118 nm with a relative narrow distribution (PDI_{DLS} = 0.104) for PCL₅₀-*b*-ABPA₃₈-*b*-POEGMEA₃₇, and an average size of 183 nm for PCL₅₀-*b*-PAPA₃₈-*b*-POEGMEA₃₇ with a PDI_{DLS} of 0.117. The obvious size difference between M1 and M2 is due to the removal of the BOC protective group on the polymer backbone to give primary amines. The repulsive forces of the positively charged amino groups lead to swelling and chain stretching and therefore an increase in micelle size.

A series of curcumin loaded micelles formulated with different amounts of curcumin (w/w, % of polymer) was prepared to study the curcumin encapsulation efficiency. The successful encapsulation was made visible by the clear yellow solution of curcumin loaded into micelles compared to free curcumin (Fig. 1). The encapsulation of curcumin is deter-

Table 3 Loading of curcumin in M1 micelles with different amounts used

Polymer used (mg)	Curcumin added (mg)	Encapsulation efficiency (%)	Entrapment efficiency (%)
15	1	87	5.8
15	2	53	6.9
15	5.5	19	6.3

mined using a UV-VIS spectrophotometer where 100 μ L of the 1 mg mL⁻¹ solution was diluted to 2 mL in DMF and a standard curve was set up as a guideline. The encapsulation efficiency of curcumin is shown in Table 3. The results showed that with a constant amount of polymer used the maximum entrapment efficiency was limited between 6 and 7 wt%. Hence, more curcumin led to a decrease in encapsulation efficiency.

At this stage, the Pt(IV) drug for conjugation to the polymer was prepared. Various deactivation pathways of Pt(II) anti-cancer drugs can be avoided using Pt(IV) compounds as pro-drugs.^{63,64} The Pt(IV) complex used in this project is based on the idea that the drug itself can be used as a crosslinker to strengthen the micelle's integrity preventing premature breakdown and reducing burst release of curcumin. In addition, this dual drug carrier was designed to sufficiently carry both drugs through the bloodstream and release a cytotoxic dose of cisplatin upon intracellular reduction once inside a tumour cell; at the same time curcumin would be released with the breakdown of the micelle. The synthesis of the platinum(IV) crosslinker requires a two-step reaction. The first step involves the oxidation of cisplatin using hydrogen peroxide solution (30%) and heat, followed by the ring opening reaction with succinic anhydride. The final product was readily soluble in water as well as DMF, therefore the unreacted complex can be easily removed by dialysis.

The attachment of the platinum(IV) crosslinker was performed in conjunction with the incorporation of curcumin. This minimises the loss of curcumin *via* diffusion during dialysis with water. The conjugation reaction was carried out at room temperature for 48 hours, and EDC and NHS were used for the esterification as the coupling agent and catalyst, respectively. The reason EDC was chosen as opposed to DCC is due to the solubility of EDC in water and can be easily removed by dialysis.

Once the curcumin was encapsulated and the micelles were crosslinked with the platinum(IV) compound, the size of the micelles (M3) were measured by DLS and results showed that the average size of these micelles has dropped dramatically to 38 nm and the size is confirmed by TEM (Fig. 1). The significant reduction in size can be explained by the loss of cationic charges during crosslinking and the force that contracts the micelle when crosslinking.

The solution was then freeze dried and redissolved in DMAC in order to evaluate the stability of these micelles in a good solvent that can dissolve all blocks. Structural integrity under these conditions confirms the success of the crosslinking process. The hydrodynamic diameter (M4) measured in DMAC

Table 2 Summary of the average hydrodynamic diameter D_h and the polydispersity index of micelles

Code	Copolymer	D_h (d nm ⁻¹)	PDI _{DLS}
M1	PCL ₅₀ - <i>b</i> -PABPA ₃₈ - <i>b</i> -POEGMEA ₃₇	118.2	0.104
M2	PCL ₅₀ - <i>b</i> -PAPA ₃₈ - <i>b</i> -POEGMEA ₃₇	183.4	0.117
M3	PCL ₅₀ - <i>b</i> -PAPA ₃₈ - <i>b</i> -POEGMEA ₃₇ cuc + Pt	28.7	0.389
M4	PCL ₅₀ - <i>b</i> -PAPA ₃₈ - <i>b</i> -POEGMEA ₃₇ cuc + Pt (freeze dried and redissolved in DMAC)	68.8	0.386
M1 cuc	PCL ₅₀ - <i>b</i> -PABPA ₃₈ - <i>b</i> -POEGMEA ₃₇ cuc	78.5	0.242
M2 Pt	PCL ₅₀ - <i>b</i> -PAPA ₃₈ - <i>b</i> -POEGMEA ₃₇ Pt	155	0.399




Fig. 1 Photograph showing the solubility of curcumin loaded M1 micelles (1 mg mL⁻¹) and the insolubility of curcumin itself in aqueous solution.





Fig. 2 TEM image of M3 micelles (loaded with cuc and crosslinked with Pt) (concentration of micelles 1 mg mL^{-1} in water): A (scale bar = 200 nm) and B (scale bar = 50 nm).

is about 68.8 nm. The increase in size is expected since the micelle would start swelling under these conditions, but not disintegrate, which is proof of evidence that crosslinking indeed occurred (Fig. 2). The overlay of the average size distribution of micelles as measured by DLS can be found in ESI Fig. S6.†

To determine the amount of platinum crosslinker conjugated to the micelle $\text{PCL}_{50}\text{-}b\text{-APA}_{38}\text{-}b\text{-POEGMEA}_{37}$ was used to synthesis blank micelles (concentration = 1 mg mL^{-1}) without the encapsulation of curcumin. The ratio between the Pt(IV) $[(\text{COOH}_2)]$ carboxyl and the polymer amine functional group was set to 2 : 1, which would in theory lead to polymers with pendant, non-crosslinked platinum drugs as depicted in Scheme 3 on the right. The ratio was chosen to ensure that all amine groups have the possibility to react to eliminate potentially toxic cationic charges. After reaction, the polymer was dialysed to remove the unreacted Pt(IV) $[(\text{COOH}_2)]$. ICP-MS was used to determine the amount of platinum attached revealing a consumption of 79% of the initial drug. Assuming all amine functional groups have reacted, further calculations disclose that out of the 38 repeating units of the amine containing monomer 41% are crosslinked and that 59% are conjugated to a platinum unit but not crosslinked (Scheme 3).

The release of curcumin was performed in three different scenarios to evaluate the rate of release with and without the crosslinking as well as compared with the decomposition of the platinum crosslinker. The amount of platinum released was determined by UV-Vis spectroscopy since the absorbance is not affected by the presence of platinum drugs. Firstly, M1 was used for the encapsulation of curcumin and the micelles were dialysed against water to measure the release of curcumin



Scheme 3 Conjugation of Pt(IV) $[(\text{COOH})_2]$ as a crosslinker for the amine bearing monomers.

in the absence of the platinated crosslinker. In another experiment, two M3 solutions (5 mL) were placed in two separate dialysis bags, one is placed in a 0.1 M PBS solution at pH 7.4 and the other in a 5 mM ascorbic acid solution. Ascorbic acid is a reducing agent which reduces the Pt(IV) complexes to Pt(II) where the compound loses its axial ligands. Studies have shown that the reduction rate of Pt(IV) complexes strongly depends on the electron-withdrawing power and the steric hindrance of the axial ligands. The rate of reduction increases in the order of axial ligands: $\text{OH} < \text{OCOCH}_3 < \text{Cl} < \text{OCOCF}_3$.⁶⁵ Samples were taken from the dialysis bag and were measured with UV-VIS spectroscopy at 428 nm in DMF to quantify the amount of curcumin remaining.

From the results obtained, the fastest release of curcumin is from the uncrosslinked micelles indicating that the flexible structure did not delay the release. After 8 hours 40% of the curcumin is released and the rate of release has slowed down for the next 2 days, reaching a maximum release of 63% in 5 days. Comparing the platinum crosslinked micelles, a faster release rate of curcumin could be observed with the reduction of the platinum crosslinker in the presence of ascorbic acid within the first 20 hours but slowly levels off to similar values of crosslinked micelles in 0.1 M PBS solution as shown in Fig. 3. In summary, crosslinking of the micelles at the interphase of hydrophilic and hydrophobic sections slows down the leaching of the encapsulated curcumin avoiding the initial burst release of the drug. Although crosslinking of micelles can result in a much more noticeable delay of the release rate,⁶⁶ the measure rate here is not a sign that crosslinking has not occurred, but more a sign that the crosslinking density is not high.

The release of platinum was measured by ICP-MS in a reductive environment of ascorbic acid and the results show that more than 50% of the platinum was released within the first 24 h and levels off to about 75% after 2 days (Fig. 3). The micelles in the absence of ascorbic acid did not release Pt-drugs.




Fig. 3 The release of curcumin (open symbol) and platinum (closed symbol) from the platinum crosslinked $\text{PCL}_{50}\text{-}b\text{-PAPA}_{38}\text{-}b\text{-POEGMEA}_{37}$ M3 micelle in both PBS (0.1 M) and ascorbic acid (5 mM) over 150 h as well as the release of curcumin from $\text{PCL}_{50}\text{-}b\text{-PABPA}_{38}\text{-}b\text{-POEGMEA}_{37}$ M1 in PBS.

The cytotoxicity effect of the curcumin and platinum incorporated micelle and the free drugs (curcumin, cisplatin, oxoplatin and platinum-diacid) was studied against A2780 cells using the standard SRB assay. First the toxicity of the polymer at various concentrations was investigated prior to drug incorporation and it can be deduced that the naked polymer itself has little or no effect on the growth of A2780 cells at low concentrations however concentrations higher than $250 \mu\text{g mL}^{-1}$ show a slight cell growth inhibition effect (Fig. 4).

Subsequently the cytotoxicity of free drugs oxoplatin, cisplatin, $\text{Pt(IV)}[(\text{COOH})_2]$ and curcumin was tested against A2780 (Fig. 5). The results were compared with the drug incorporated micelles; the comparison allows the determination of the efficacy of the drug carriers themselves. As expected, cisplatin is more potent than oxoplatin as oxoplatin is a platinum(IV) compound, which requires an extra reduction step to form the active diaquo-diamino platinate(II) active species in order to bind to DNA to cause cell apoptosis. Furthermore, cisplatin is more potent towards the A2780 cells than curcumin, $\text{Pt}[(\text{COOH})_2]$ and oxoplatin, where A2780 cells are least suscep-




Fig. 4 Human Ovarian Carcinoma A2780 viability after being exposed to a solution containing M1 after 48 h.




Fig. 5 Cell growth inhibition study of curcumin, Pt-diacid, cisplatin and oxoplatin against A2780 human ovarian carcinoma cancer cells for 48 h.

Table 4 IC_{50} values for compounds tested on the A2780 cell line after 48 h exposure

Compound	$\text{IC}_{50} (\mu\text{g mL}^{-1} \text{ of the drug})$	$\text{IC}_{50} \mu\text{M}$
Oxoplatin	38.22	114.8
Cisplatin	3.99	13.3
$\text{Pt(IV)}[(\text{COOH})_2]$	97.38	172.0
Curcumin	83.72	227
M1 cuc	26.24	71.3
M2 Pt	16.47	29.1
M3	Pt: 12.08 Cuc: 8.68	Pt: 21.3 Cuc: 23.5

tible to curcumin, giving the highest IC_{50} value. IC_{50} values of all compounds tested are shown in Table 4.

Drug incorporated micelles were also tested against the A2780 human ovarian cancer cell line. The purpose of this experiment was to demonstrate the importance of drug delivery systems for the enhanced cytotoxicity compared to free drugs. Three micelles were compared: a micelle loaded with curcumin only using $\text{PCL}_{50}\text{-}b\text{-PAPA}_{38}\text{-}b\text{-POEGMEA}_{37}$ (M1 cuc), a micelle crosslinked with $\text{Pt(IV)}[(\text{COOH})_2]$ (M2 Pt micelle) and a micelle loaded with both drugs (M3). The molar ratio of curcumin and Pt in the latter micelle was measured by UV-Vis spectroscopy and ICP-MS to be 1 : 0.95 indicating that roughly the same molar amounts of both drugs are present in the system.

The IC_{50} of free curcumin was compared with curcumin incorporated micelles in the same way as curcumin encapsulated platinum crosslinked micelles were compared with each other (Fig. 6). The results show that with the aid of the polymeric drug delivery system, the cytotoxicity of curcumin is increased compared with the free drug. The decrease in IC_{50} from $83.72 \mu\text{g mL}^{-1}$ to $26.24 \mu\text{g mL}^{-1}$ with the use of polymeric micelles most likely indicates the efficiency of transporting larger amounts of curcumin into the cell by endocytosis rather than through ion channels. PEG-based micelles are known to be efficiently taken up by various cells while simultaneously transporting large amounts of drug across the cell




Fig. 6 Cell growth inhibition study of free curcumin, curcumin incorporated micelles and curcumin platinum crosslinked micelles against A2780 human ovarian cancer cells for 48 h.




Fig. 7 Cell growth inhibition study of free Pt[(COOH)₂], M2-Pt micelles and curcumin platinum crosslinked micelles M3 against A2780 human ovarian cancer cells for 48 h.

membrane.^{67–69} In addition, studies have shown that when curcumin accumulates in the endoplasmic reticulum (ER) membrane, the intracellular iron pool is reduced. This may result in lengthening of the G1 phase of the cell cycle, thereby slowing growth *in vitro*.⁷⁰

Similar results were found when investigating the platinum drug loaded micelle with the drug being less toxic compared to platinum crosslinked micelles (Fig. 7). The reason is that micelles are internalised by endocytosis and the platinum complex attached to the polymer backbone will undergo a reduction process in the cell cytoplasm and thus platinum(II) will be released. Once enough platinum(IV) has been cleaved off the backbone the structural integrity of the micelle becomes unstable and it eventually falls apart. This in turn gives the lower IC₅₀ value compared to the free Pt[(COOH)₂] complex. With the aid of curcumin the IC₅₀ value of micelles containing both drugs is again lower than the micelles containing only Pt[(COOH)₂].

The computer software CalcuSyn for Windows (Biosoft, UK) was employed to evaluate the synergistic effect between curcumin and Pt[(COOH)₂] as free drugs as well as micelle-incorporated moieties. In this system, synergism, additivity, or antagonism is defined by the combination index; a CI value <1 indicates the synergistic effect, a CI value of 1 indicates an additive effect and a CI value >1 indicates an antagonistic effect.

The experimental set up consisted of constant concentration ratios between curcumin and Pt[(COOH)₂] against A2780 cells individually and combined as free drugs, mixed micelles and as well being incorporated in micelles. The results are represented in an Isobologram as well as a Median effect analysis plot (Fig. 8). Details of the analysis can be found in the ESI.†

The experimental data are represented in dots and data points that are located below the line in the median effect analysis indicating their synergism within the fractional effect between zero and one. The fractional effect on cell death is calculated by the formula: (100-alive cells)/100. The calculation




Fig. 8 CalcuSyn software evaluation of the synergistic effect of free curcumin and free Pt(IV) acid complex as an isobologram (A) and Median effect analysis plot (B), the mixture effect of two separate micelle solutions as an isobologram (C) and Median effect analysis plot (D), the effect of both drugs in one micelle as an isobologram (E) and Median effect plot (F).

using the computer software CalcuSyn of the *in vitro* experimental results showed the synergistic effect of curcumin and Pt[(COOH)₂] in 1 : 1 ratio as free drugs (Fig. 8A and B). This can also be seen for the combination of the two drugs in one micelle in the same ratio of curcumin to Pt[(COOH)₂] (Fig. 8E and F). However, it appears that the synergistic effect of the mixture of two individual drugs encapsulated in micelles is prominent at low fractional effects. From the refined values from the combination index method described by Chou and Talalay it can be seen that the combination of curcumin and Pt[(COOH)₂] as free drugs (CI values between 0.3 and 0.7) is less synergistic compared to the micelle form (CI values between 0.1 and 0.4).

Here, it can be seen that the combination of free Pt[(COOH)₂] and curcumin results in marked synergy (Fig. 8B), where the combination indices all range between 0.4 and 0.8. When the same drugs are incorporated into micelles in the same concentration ratios, the combination indices are mostly less than 0.4 and reach 0.2 (Fig. 8D), indicating highly synergistic combinations. These data confirm that the combination of cisplatin and curcumin is synergistic, but also that the incorporation of both drugs in micelles increases the synergy considerably. At this point, it is not clear why the behaviour is different between the micelle loaded with both drugs and two micelles loaded with curcumin and platinum drug respectively. It is possible that different uptake pathways of the two different micelles can result in this outcome while drugs

loaded into one carrier will have the same uptake pathway together.

Conclusion

This project demonstrated the enhanced cytotoxicity of micelles incorporating two drugs as combinational chemotherapy against a resistant cancer cell line. A triblock copolymer was synthesised with amphiphilic properties to allow the physical encapsulation of curcumin and it also allows for the crosslinking using $\text{Pt}(\text{NH}_3)_2\text{Cl}_2[(\text{COOH})_2]$ at the interphase which strengthens the structural integrity of the micelle to ensure a slower release of curcumin and to prevent premature disassociation of the delivery vehicle. The synergistic effect of both drugs as free drugs as well as in the micelle form is calculated using the CalcuSyn Biosoft software which indicates that the use of both drugs is a highly synergistic combination.

Acknowledgements

The authors would like to thank the Australian Research Council (ARC) for funding. M. H. Stenzel and W. Scarano acknowledge the Centre for Advanced Macromolecular Design (CAMD), the St George Research Education Centre (CPT), the UNSW Analytical Centre for support and the UNSW Electron Microscope Unit for support.

References

- 1 M. M. Gottesman, *Annu. Rev. Med.*, 2002, **53**, 615–627.
- 2 K. Kataoka, A. Harada and Y. Nagasaki, *Adv. Drug Delivery Rev.*, 2012, **64**(Supplement), 37–48.
- 3 R. Haag, *Angew. Chem., Int. Ed.*, 2004, **43**, 278–282.
- 4 E. M. McKelvey, J. A. Gottlieb, H. E. Wilson, A. Haut, R. W. Talley, R. Stephens, M. Lane, J. F. Gamble, S. E. Jones, P. N. Grozea, J. Guttermann, C. Coltmann and T. E. Moon, *Cancer*, 1976, **38**, 1484–1493.
- 5 T. Tippiayamontri, R. Kotb, B. Paquette and L. Sanche, *Anti-cancer Res.*, 2013, **33**, 3005–3014.
- 6 R. Yang, B. Wang, Y.-J. Chen, H.-B. Li, J.-B. Hu and S.-Q. Zou, *Anti-Cancer Drugs*, 2013, **24**, 871–877.
- 7 Z. H. Lu, J. Li, M. Lu, X. T. Zhang, J. Zhou, X. C. Wang, J. F. Gong, J. Gao, Y. Li and L. Shen, *Med. Oncol.*, 2013, **30**, 664–664.
- 8 P. Prasad, A. Shuhendler, P. Cai, A. M. Rauth and X. Y. Wu, *Cancer Lett.*, 2013, **334**, 263–273.
- 9 V. Brabec and J. Kasparkova, *Drug Resist. Updates*, 2005, **8**, 131–146.
- 10 L. Kelland, *Nat. Rev. Cancer*, 2007, **7**, 573–584.
- 11 R. J. Knox, F. Friedlos, D. A. Lydall and J. J. Roberts, *Cancer Res.*, 1986, **46**, 1972–1979.
- 12 E. Wong and C. M. Giandomenico, *Chem. Rev.*, 1999, **99**, 2451–2466.
- 13 Y.-W. Lin, M.-S. Tsai, S.-H. Weng, Y.-H. Kuo and Y.-F. Chiu, *Mol. Pharm.*, 2011, **255**(3), 327–338.
- 14 F. Payton, P. Sandusky and W. L. Alworth, *J. Nat. Prod.*, 2007, **70**, 143–146.
- 15 P. Anand, C. Sundaram, S. Jhurani, A. B. Kunnumakkara and B. B. Aggarwal, *Cancer Lett.*, 2008, **267**, 133–164.
- 16 M. Hollborn, R. Chen, P. Wiedemann, A. Reichenbach, A. Bringmann and L. Kohen, *PLoS One*, 2013, **8**.
- 17 P. Kuppusamy, K. Hideg and H. Kalman, Univ Ohio State Res Found.
- 18 G. R. Pillai, A. S. Srivastava, T. I. Hassanein, D. P. Chauhan and E. Carrier, *Cancer Lett.*, 2004, **208**, 163–170.
- 19 A. Saha, T. Kuzuhara, N. Echigo, A. Fujii, M. Suganuma and H. Fujiki, *Biol. Pharm. Bull.*, 2010, **33**, 1291–1299.
- 20 R. K. Maheshwari, A. K. Singh, J. Gaddipati and R. C. Srimal, *Life Sci.*, 2006, **78**, 2081–2087.
- 21 Q. Chen, Y. Wang, K. Xu, G. Lu, Z. Ying, L. Wu, J. Zhan, R. Fang, Y. Wu and J. Zhou, *Oncol. Rep.*, 2010, **23**, 397–403.
- 22 Q. Y. Chen, G. H. Lu, Y. Q. Wu, Y. Zheng, K. Xu, L. J. Wu, Z. Y. Jiang, R. Feng and J. Y. Zhou, *Oncol. Rep.*, 2010, **23**, 1285–1292.
- 23 A. O. Boztas, O. Karakuzu, G. Galante, Z. Ugur, F. Kocabas, C. Z. Altuntas and A. O. Yazaydin, *Mol. Pharm.*, 2013, **10**, 2676–2683.
- 24 Q. Du, B. Hu, H.-M. An, K.-P. Shen, L. Xu, S. Deng and M.-M. Wei, *Oncol. Rep.*, 2013, **29**, 1851–1858.
- 25 M. M. Hossain, N. L. Banik and S. K. Ray, *Neurochem. Int.*, 2012, **61**, 1102–1113.
- 26 D. Sutaria, B. K. Grandhi, A. Thakkar, J. Wang and S. Prabhu, *Int. J. Oncol.*, 2012, **41**, 2260–2268.
- 27 A. Cort, M. Timur, E. Ozdemir, E. Kucuksayan and T. Ozben, *Mol. Med. Rep.*, 2012, **5**, 1481–1486.
- 28 R. Manikandan, M. Beulaja, C. Arulvasu, S. Sellamuthu, D. Dinesh, D. Prabhu, G. Babu, B. Vaseeharan and N. M. Prabhu, *Microsc. Res. Tech.*, 2012, **75**, 112–116.
- 29 H. Yin, R. Guo, Y. Xu, Y. Zheng, Z. Hou, X. Dai, Z. Zhang, D. Zheng and H. e. Xu, *Acta Biochim. Biophys. Sin.*, 2012, **44**, 147–153.
- 30 M. A. Parasramka and S. V. Gupta, *J. Oncol.*, 2012, **2012**, 709739–709739.
- 31 R. A. Siddiqui, J. D. Altenburg, A. A. Bieberich, K. A. Harvey, Z. Xu and V. J. Davisson, *FASEB J.*, 2011, **25**.
- 32 B. B. Patel and A. P. N. Majumdar, *Nutr. Cancer*, 2009, **61**, 842–846.
- 33 T. M. Elattar and A. S. Virji, *Anticancer Res.*, 2000, **20**, 1733–1738.
- 34 M. Sun, X. Su, B. Ding, X. He, X. Liu, A. Yu, H. Lou and G. Zhai, *Nanomedicine*, 2012, **7**, 1085–1100.
- 35 H. Maeda, *J. Controlled Release*, 2012, **164**, 138–144.
- 36 H. Maeda, *Cancer Sci.*, 2013, **104**, 779–789.
- 37 H. Maeda, H. Nakamura and J. Fang, *Adv. Drug Delivery Rev.*, 2013, **65**, 71–79.
- 38 J. Fang, H. Nakamura and H. Maeda, *Adv. Drug Delivery Rev.*, 2011, **63**, 136–151.
- 39 H. Maeda, G. Y. Bharate and J. Daruwalla, *Eur. J. Pharm. Biopharm.*, 2009, **71**, 409–419.

- 40 J.-C. Tang, H.-S. Shi, L.-Q. Wan, Y.-S. Wang and Y.-Q. Wei, *Asian Pacific J. Cancer Prev.*, 2013, **14**, 2307–2310.
- 41 M. Gou, K. Men, H. Shi, M. Xiang, J. Zhang, J. Song, J. Long, Y. Wan, F. Luo, X. Zhao and Z. Qian, *Nanoscale*, 2011, **3**, 1558–1567.
- 42 L. Liu, L. Sun, Q. Wu, W. Guo, L. Li, Y. Chen, Y. Li, C. Gong, Z. Qian and Y. Wei, *Int. J. Pharm.*, 2013, **443**, 175–182.
- 43 Z. Ma, A. Haddadi, O. Molavi, A. Lavasanifar, R. Lai and J. Samuel, *J. Biomed. Mater. Res., Part A*, 2008, **86A**, 300–310.
- 44 K. Wang, T. Zhang, L. Liu, X. Wang, P. Wu, Z. Chen, C. Ni, J. Zhang, F. Hu and J. Huang, *Int. J. Nanomed.*, 2012, **7**, 4487–4497.
- 45 S. Manju and K. Sreenivasan, *J. Colloid Interface Sci.*, 2012, **368**, 144–151.
- 46 L. M. Howells, S. Sale, S. N. Sriramareddy, G. R. B. Irving, D. J. L. Jones, C. J. Ottley, D. G. Pearson, C. D. Mann, M. M. Manson, D. P. Berry, A. Gescher, W. P. Steward and K. Brown, *Int. J. Cancer*, 2011, **129**, 476–486.
- 47 M. Al Moundhri, S. Al-Salam, A. Al Mahrouqee, S. Beegam and B. Ali, *J. Med. Toxicol.*, 2013, **9**, 25–33.
- 48 M. U. Nessa, P. Beale, C. Chan, J. Q. Yu and F. Huq, *Anti-cancer Res.*, 2012, **32**, 4843–4850.
- 49 M. Notarbartolo, P. Poma, D. Perri, L. Dusonchet, M. Cervello and N. D'Alessandro, *Cancer Lett.*, 2005, **224**, 53–65.
- 50 L. Li, B. Ahmed, K. Mehta and R. Kurzrock, *Mol. Cancer Ther.*, 2007, **6**, 1276–1282.
- 51 V. T. Huynh, S. Pearson, J. M. Noy, A. Abboud, R. H. Utama, H. X. Lu and M. H. Stenzel, *ACS Macro Lett.*, 2013, **2**, 246–250.
- 52 V. T. Huynh, J. Y. Quek, P. L. de Souza and M. H. Stenzel, *Biomacromolecules*, 2012, **13**, 1010–1023.
- 53 M. Callari, J. Aldrich-Wright, P. L. de Souza and M. H. Stenzel, *Prog. Polym. Sci.*, 2014, **39**(9), 1614–1643.
- 54 H. T. T. Duong, V. T. Huynh, P. de Souza and M. H. Stenzel, *Biomacromolecules*, 2010, **11**, 2290–2299.
- 55 Y. Kim, M. H. Pourgholami, D. L. Morris, H. Lu and M. H. Stenzel, *Biomater. Sci.*, 2013, **1**, 265–275.
- 56 V. T. Huynh, S. Binauld, P. L. de Souza and M. H. Stenzel, *Chem. Mater.*, 2012, **24**, 3197–3211.
- 57 J. Skey and R. K. O'Reilly, *Chem. Commun.*, 2008, 4183–4185.
- 58 A. Gregory and M. H. Stenzel, *Prog. Polym. Sci.*, 2012, **37**, 38–105.
- 59 D. R. Chen, J. Z. Bei and S. G. Wang, *Polym. Degrad. Stab.*, 2000, **67**, 455–459.
- 60 S. Sinnwell, A. J. Inglis, T. P. Davis, M. H. Stenzel and C. Barner-Kowollik, *Chem. Commun.*, 2008, 2052–2054.
- 61 J. Xu, J. He, D. Fan, X. Wang and Y. Yang, *Macromolecules*, 2006, **39**, 8616–8624.
- 62 C. Boyer, A. Granville, T. P. Davis and V. Bulmus, *J. Polym. Sci., Part A: Polym. Chem.*, 2009, **47**, 3773–3794.
- 63 S. v. Zutphen and J. Reedijk, *Coord. Chem. Rev.*, 2005, **249**, 2845–2853.
- 64 N. J. Wheate, S. Walker, G. E. Craig and R. Oun, *Dalton Trans.*, 2010, **39**, 8113–8127.
- 65 S. Choi, C. Filotto, M. Bisanzo, S. Delaney, D. Lagasee, J. L. Whitworth, A. Jusko, C. Li, N. A. Wood, J. Willingham, A. Schwenker and K. Spaulding, *Inorg. Chem.*, 1998, **37**, 2500–2504.
- 66 Y. Kim, M. H. Pourgholami, D. L. Morris and M. H. Stenzel, *Biomacromolecules*, 2012, **13**, 814–825.
- 67 A. Kumari, S. K. Yadav and S. C. Yadav, *Colloids Surf., B*, 2010, **75**, 1–18.
- 68 K. Knop, R. Hoogenboom, D. Fischer and U. S. Schubert, *Angew. Chem., Int. Ed.*, 2010, **49**, 6288–6308.
- 69 A. Mero, O. Schiavon, G. Pasut, F. M. Veronese, E. Emilietri and P. Ferruti, *J. Bioact. Compat. Polym.*, 2009, **24**, 220–234.
- 70 S. Minear, A. F. O'Donnell, A. Ballew, G. Giaever, C. Nislow, T. Stearns and M. S. Cyert, *Eukaryotic Cell*, 2011, **10**, 1574–1581.